CVS, Teva, Allergan and Endo reach $878 million deal with Florida over the opioid crisis - STAT
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
The Difficulties of Cloning a CEO - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva Cites 'Havoc' as It Takes Drug Label Spat to Supreme Court (1)
Justice Dept reportedly may file charges in its generic-drug probe by year-end
Teva Stares Into Abyss as It Slashes Forecast, Dividends - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Pharmaceutical: Value at Last - WSJ
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
With New Teva Deal, Combined NY Settlements With Opioid Makers Top $2 Billion | New York Law Journal
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
